{
  "pmcid": "5831461",
  "abstract": "250-word version:\n\nTitle: Intraoperative Dexmedetomidine and Postoperative Delirium: A Randomised Controlled Trial\n\nBackground: Postoperative delirium affects 10% to 60% of elderly patients undergoing major surgery, leading to longer hospital stays and increased mortality. Dexmedetomidine sedation in critical care units has been linked to reduced delirium, but its intraoperative use remains underexplored.\n\nMethods: This multicenter, double-blind, randomized, placebo-controlled trial involved elderly patients (>68 years) undergoing major elective noncardiac surgery. Participants were randomized to receive either dexmedetomidine (0.5 Âµg/kg/h) or saline placebo during surgery and for 2 hours postoperatively. The primary outcome was postoperative delirium, assessed daily. Secondary outcomes included postoperative cognitive decline. Randomization was computer-generated, with allocation concealed using sealed envelopes. Blinding included patients, clinicians, and outcome assessors. Recruitment occurred from February 2008 to May 2014.\n\nResults: A total of 404 patients were randomized (202 to dexmedetomidine, 202 to placebo); 390 completed delirium assessments. Postoperative delirium incidence was similar between groups (12.2% dexmedetomidine vs 11.4% placebo, P = .94). No significant differences in cognitive performance were observed at 3 and 6 months postoperatively. Adverse events were similar across groups.\n\nInterpretation: Intraoperative dexmedetomidine does not reduce postoperative delirium, contrasting with previous findings in intensive care settings. Timing of administration may be crucial. Trial registration: NCT00561678. Funding: Not specified.",
  "word_count": 206
}